|
KMID : 1148920080420040307
|
|
Nuclear Medicine and Molecular Imaging
2008 Volume.42 No. 4 p.307 ~ p.313
|
|
|
Evaluation of the Radioimmunotherapy Using I-131 Labeled Vascular Endothelial Growth Factor Receptor2 Antibody in Melanoma Xenograft Murine Model
|
|
Kim Eun-Mi
Jeong Hwan-Jeong
Park Eun-Hye
Cheong Su-Jin
Lee Chang-Moon
Jang Kyu-Yun
Kim Dong-Wook
Lim Seok-Tae
Sohn Myung-Hee
|
|
|
Abstract
|
|
|
Purpose: Vascular endothelial growth factor (VEGF) and its receptor, fetal liver kinase 1 (Flk-1), play an important role in vascular permeability and tumor angiogenesis. The aim of this study is to evaluate the therapeutic efficacy of 131I labeled anti-Flk-1 monoclonal antibody (DC101) on the growth of melanoma tumor, which is known to be very aggressive in vivo.
Materials and Methods: Balb/c nude mice were injected subcutaneously with melanoma cells in the right flank. Tumors were allowed to grow up to 200-250 mm3 in volume. Gamma camera imaging and biodistribution studies were performed to identify an uptake of 131I-DC101 in various organs. Mice with tumor were randomly divided into five groups (10 mice per group) and injected intravenously; control PBS (group 1), 131I-DC101 50 μg/mouse (group 2), non-labeled DC101 50 μg/mouse (group 3), 131I-DC101 30 μg/mouse (group 4) and 15 μg/mouse (group 5) every 3 or 4 days for 20 days. Tumor volume was measured with caliper twice a week.
Results: In gamma camera images, the uptake of 131I-DC101 into tumor and thyroid was increased with time. Biodistribution results showed that the radioactivity of blood and other major organ was gradually decreased with time whereas tumor uptake was increased up to 48 hr and then decreased. After 4th injection of 131I-DC101, tumor volume of group 2 and 4 was significantly smaller than that group 1. After 5th injection, the tumor volume of group 5 also significantly reduced.
Conclusion: These results indicated that delivery of 131I to tumor using Flk-1 antibody, DC101, effectively blocks tumor growth in aggressive melanoma xenograft model.
|
|
|
KEYWORD
|
|
|
adioimmunotherapy, vascular endothelial growth factor receptor 2, melanoma
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|